Table 6 Impact of baseline immunomodulatory therapies on key outcomes in the PRESS cohort
Progression | Patients with immunomodulatory therapies at baseline | Patients without immunomodulatory therapies at baseline | P-value |
|---|---|---|---|
Patients with skin progression during the entire follow-up | 30/142 (21.1%) | 18/86 (20.9%) | 0.9719 |
Patient with FVC decline during the entire follow-up | 27/114 (23.7%) | 14/62 (22.6%) | 0.8686 |
Death at the end of the study | 10/190 (5.3%) | 10/111 (9.0%) | 0.2081 |